Onconova Announces Multiple Rigosertib Clinical Data

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Onconova Announces Multiple Rigosertib Clinical Data Presentations at the 2015 ASCO Annual Meeting

NEWTOWN, Pa., May 13, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq: ONTX ), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that two abstracts are being presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, IL, May 29 – June 2, 2015.

Data Analysis of Phase 3 ONTIME Trial:

Abstract #7092 Title: Prognostic and predictive value of IPSS-R in assessing overall survival (OS) in a phase III study of rigosertib in second-line higher-risk (HR) MDS patients. Date: Sunday, May 31, 2015 Time: 8:00 AM – 11:30 AM Session: Leukemia, Myelodysplasia, and Transplantation Location: McCormick Place, S Hall A Presenter: Lewis R. Silverman, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

Abstract #7017 Title: Correlation of overall survival (OS) with bone marrow blast (BMBL) response in patients (pts) with myelodysplastic syndrome. Date: Sunday, May 31, 2015 Time: 8:00 AM – 11:30 AM Session: Leukemia, Myelodysplasia, and Transplantation Location: McCormick Place, S Hall A Presenter: Lewis R. Silverman, MD, Division of Hematology/Oncology, Icahn School of Medicine at Mount Sinai, New York, NY

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, the Company's most advanced product candidate, two other candidates are clinical stage, and several candidates are in pre-clinical stages. For more information, please visit http://www.onconova.com .

About Rigosertib

Rigosertib is a small molecule that inhibits cellular signaling by acting as a Ras mimetic. This is believed to be mediated by direct binding of rigosertib to the Ras-binding domain (RBD) found in many Ras effector proteins, including the Raf kinases and PI3K. The initial therapeutic focus for rigosertib is myelodysplastic syndromes (MDS), a group of bone marrow disorders characterized by ineffective formation of blood cells that often converts into acute myeloid leukemia (AML). Clinical trials with intravenous (IV) and oral formulations of rigosertib are being conducted at leading institutions in the U.S. and Europe.

About the ONTIME Trial

The ONTIME Trial, a Phase 3 multi-center, randomized, controlled study assessed the efficacy and safety of rigosertib 72-hour continuous intravenous infusion plus best supportive care (BSC) compared to BSC alone, in higher-risk MDS patients with excess blasts (5% to 30% bone marrow blasts), who had progressed on, failed or relapsed after treatment with HMAs. Results of stratified and exploratory subgroup analyses, demonstrating heterogeneity in the study population, were presented at the 2014 American Society of Hematology Annual Meeting (Garcia-Manero et al., Abstract 163). The ONTIME trial did not meet its primary endpoint in the intent-to-treat population, but improvements in median overall survival (mOS) were observed in various pre-specified and exploratory subgroups of patients, including "primary HMA failure" patients (those who had progressed on or failed to respond to previous treatment with HMAs) and patients in the Revised International Prognostic Scoring System (IPSS-R) Very High Risk category (IPSS-R calculates a risk score for MDS patients based on the location and type of chromosome abnormalities, number and degree of cytopenias, and percentage of bone marrow blasts observed at diagnosis). Among the 184 patients (62% of patients in the trial) with primary HMA failure, mOS was 8.6 months in the rigosertib arm (127 patients) compared to 5.3 months in the best supportive care arm (57 patients), with a hazard ratio of 0.69 and a p value of 0.040. Among the 134 patients (45% of patients in the trial) who were in the IPSS-R Very High Risk category, mOS was 7.6 months in the rigosertib arm (93 patients) compared to 3.2 months in the best supportive care arm (41 patients), with a hazard ratio of 0.56 and a p value of 0.005. Further, the safety and tolerability of rigosertib IV in the ONTIME trial was acceptable.

Forward Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. These statements relate to future events or Onconova Therapeutics, Inc.'s future operations, clinical development of Onconova's product candidates and presentation of data with respect thereto, regulatory approvals, expectations regarding the sufficiency of Onconova's cash and other resources to fund operating expenses and capital expenditures, Onconova's anticipated milestones and future expectations and plans and prospects. Although Onconova believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Onconova has attempted to identify forward-looking statements by terminology including "believes," "estimates," "anticipates," "expects," "plans," "intends," "may," "could," "might," "will," "should," "approximately" or other words that convey uncertainty of future events or outcomes. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under the heading "Risk Factors" in our most recent Annual Report on Form 10-K and quarterly reports on Form 10-Q.

Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Onconova Therapeutics Benjamin Hoffman, 267-759-3036

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Sungrow's Keeper Family: Revolutionizing C&I Energy Storage

Updated Category News Views 102

The Next Level in Energy Storage Solutions Well, folks, Sungrow's got something up its sleeve that's shaking up the energy storage scene. They're calling it the 'Keeper Family,' and if you’re deep into commercial and industrial (C&I) energy storage, this might just be your ticket to topping those profit charts. Launched at the Global Energy Pioneer Summit 2026, their...

Continue Reading
Gary Brecka's Longevity Centers Set to Launch with Impact

Updated Category News Views 0

A Footprint of Longevity in the Making It's not every day you see a name like Daymond John, of Shark Tank fame, getting his hands into the business of human longevity. But here we are, with Gary Brecka's Ultimate Longevity Center (ULC) getting ready to open its first centers come January 2027, in Arizona, Colorado, Florida, and Southern California. More than 300 U.S....

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 0

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Rock Tech Uncovers Major Lithium Discovery at Victory

Updated Category News Views 28

Rock Tech's Game-Changer at Victory Folks, we've got a shake-up in the lithium landscape over in Ontario, courtesy of Rock Tech Lithium Inc. They just unearthed something quite promising at their Victory Project: a spanking new spodumene-bearing pegmatite discovery. Now I know, if you're like me, you're thinking, 'What's the angle here?' Well, this isn't just another hole...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 116

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Midea's R290 Tech: Real Green Cooling Revolution?

Updated Category News Views 215

A Fresh Breeze in Sustainable Cooling In the middle of Kigali’s innovation oasis, Midea RAC stood out at MOP38, the 38th Meeting of the Parties to the Montreal Protocol, flexing its sustainable tech muscles. We're talking about their R290 air conditioning technology—a natural refrigerant with zero ozone footprint and a global warming potential of a mere three. This is...

Continue Reading
Peptide Tracker Refresh Unveils New Planning Features

Updated Category News Views 0

Peptide Tracker's Latest Updates: A Game Changer? I'll tell you what—if you're keeping tabs on your peptide intake like a seasoned gardener checks the soil, Peptide Tracker's fresh versions 3.2.0 and 3.3.0 might just be your new best mates. With the addition of washout scheduling and a robust six-month schedule preview, this isn't just another fancy tech update. It's...

Continue Reading
Scientific Games Joins NCPG’s 2026 Campaign Again

Updated Category News Views 39

Scientific Games Backs Responsible Gaming Again It's another year, and here's Scientific Games once more, guns blazing for a cause that's needed more than a few times over—responsible gambling. Those folks got their hearts in the right place, joining the National Council on Problem Gambling's 2026 Gift Responsibly campaign. Ninth time running, no less! It's like...

Continue Reading
TOYO Slips on Earnings Amid Strategic Expansion

Updated Category News Views 126

TOYO's Solar Journey: Ups and Downs If there's one thing riding high on volatility these days, it's solar energy. TOYO Co., Ltd. (Nasdaq: TOYO) spilled the beans on Q3 2026, and oh boy, it's a mixed bag. Revenue Jumps, Yet Profitability Takes a Hit Let's cut to the chase: the third quarter served up a 4.8% dip in revenue year-over-year, landing at $129 million, though it...

Continue Reading
Palatin's Game-Changer: MC4R Agonist Hits the Stage

Updated Category News Views 49

Breaking New Ground in Obesity Treatment Palatin Technologies is stepping into the spotlight with some heavy ammunition in the fight against obesity. The company has just unveiled impressive preclinical data about their next-generation melanocortin-4 receptor (MC4R) agonists at the ObesityWeek® 2026 conference. This isn’t just your run-of-the-mill corporate...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Line-Up of Athletes for Future Games in Abu Dhabi

Updated Category News Views 298

Global Stars Confirmed for Games of the Future 2025 Some of the biggest names in phygital sports and esports from around the world will head to Abu Dhabi for the ultimate showdown in next-gen sports from 18-23 December. Phygital International, the UAE-based promoter of phygital sports globally, has just confirmed the lineup for the Games of the Future Abu Dhabi 2025 (GOTF...

Continue Reading
Rhythm Pharmaceuticals Earnings Report: What to Watch For

Updated Category News Views 239

Eyes on Rhythm Pharmaceuticals: Earnings Just Around the Corner A steady hum of anticipation is in the air as Rhythm Pharmaceuticals (NASDAQ:RYTM) gears up to unveil its quarterly earnings on February 26, 2026. While investors hung onto the last report’s fallout, expectations this time are swirling around whether RYTM can turn things around after a slip last quarter....

Continue Reading
First Capital REIT Reports Impressive Q3 2024 Growth Metrics

Updated Category News Views 239

First Capital REIT's Strong Q3 Results Highlight Robust Performance First Capital Real Estate Investment Trust (TSX: FCR) has announced remarkable financial results for the third quarter ending September 30, indicating robust operational performance backed by strong leasing activities. The detailed report is made accessible to investors on the Trust's official website....

Continue Reading
Sherwin-Williams Faces Challenges After Lowering Earnings Outlook

Updated Category News Views 168

Sherwin-Williams Adjusts Earnings Projections Following Q2 Results The Sherwin-Williams Company (NYSE: SHW) recently faced some challenges after reporting lower-than-expected second-quarter earnings. With adjusted earnings per share (EPS) of $3.38, the results fell short of Wall Street's predictions, which had estimated $3.81 per share. The company's quarterly revenue,...

Continue Reading
Oculis Financial Results & Clinical Update for Q2 2024

Updated Category News Views 108

Oculis Reports Q2 Financial Results and Company Update Oculis Holding AG (NASDAQ: OCS; XICE: OCS), a global biopharmaceutical company focused on improving eye care, has shared its latest financial results and significant developments. The highlights from the second quarter ending June 30, 2024, illustrate the company's dedication to advancing its innovative clinical...

Continue Reading